XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Business Acquisition - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 23, 2020
Dec. 18, 2020
Sep. 14, 2020
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Business Acquisition [Line Items]              
Common stock, par value         $ 0.001   $ 0.001
Goodwill         $ 48,648,000   $ 48,648,000
Business acquisition costs       $ 2,700,000 $ 0 $ 2,700,000  
General and Administrative [Member]              
Business Acquisition [Line Items]              
Business acquisition costs             $ 2,900,000
Series X1 Non-voting Convertible Preferred Stock [Member]              
Business Acquisition [Line Items]              
Preferred stock, par value   $ 0.001     $ 0.001   $ 0.001
Issuance of common stock in connection with conversion of Series X preferred stock, Shares   231,068          
Preferred stock, shares outstanding         108,070   108,070
Common Stock [Member]              
Business Acquisition [Line Items]              
Shares of common stock issued upon conversion of each share of preferred stock   12,837,056          
Common Stock [Member]              
Business Acquisition [Line Items]              
Issuance of common stock in connection with conversion of Series X preferred stock, Shares           182,500  
Shares of common stock sold 1,004,111            
Proceeds from issuance of common stock $ 9,000,000.0            
Anelixis [Member]              
Business Acquisition [Line Items]              
Business acquisition, date of acquisition     Sep. 14, 2020        
Common stock, par value     $ 0.001        
Goodwill     $ 48,648,000        
Estimated fair value related to clinical development program     32,386,000        
Anelixis [Member] | In-Process Research and Development [Member]              
Business Acquisition [Line Items]              
Estimated fair value related to clinical development program     $ 32,400,000        
Anelixis [Member] | Series X1 Preferred Stock [Member]              
Business Acquisition [Line Items]              
Shares Issued to stockholders of acquiree     140,026        
Anelixis [Member] | Series X1 Preferred Stock [Member] | Stock Purchase Agreement [Member]              
Business Acquisition [Line Items]              
Preferred stock shares agreed to sell     199,112        
Preferred stock shares aggregate purchase price     $ 99,100,000        
Business combination additional commitments in equity financing     $ 9,000,000.0        
Anelixis [Member] | Common Stock [Member]              
Business Acquisition [Line Items]              
Shares Issued to stockholders of acquiree     175,488        
Shares of common stock issued upon conversion of each share of preferred stock     55.5556